Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Authors: Andrew Conroy, David E. Stockett, Duncan Walker, Michelle R. Arkin, Ute Hoch, Judith A. Fox, Rachael Elizabeth Hawtin

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Purpose

SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clinical trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis. We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.

Methods

Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS analysis to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.

Results

SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9. Treatment of RPMI-8226 MM cells at 300 nM (IC90) for 6 h was sufficient for commitment to apoptosis. This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling molecules. SNS-032 activity was unaffected by human serum. Target modulation was observed in PBMC from treated patients.

Conclusions

These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis. Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clinical study of SNS-032 in MM and CLL.
Literature
1.
Senderowicz AM, Sausville EA (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92:376–387PubMedCrossRef
2.
Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783PubMedCrossRef
3.
Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408–9421PubMedCrossRef
4.
Sharma SV, Fischbach MA, Haber DA, Settleman J (2006) “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12:4392–4395CrossRef
5.
Wickremasinghe RG, Hoffbrand AV (1999) Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 93:3587–3600PubMed
6.
Belinda C, Baliga SK (2002) Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20:63–74CrossRef
7.
Wuilleme-Toumi S, Robillard N, Gomez P et al (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19:1248–1252PubMedCrossRef
8.
MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407PubMedCrossRef
9.
Derenne S, Monia B, Dean NM et al (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 100:194–199PubMedCrossRef
10.
Nurse P (2002) Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 22:487–499PubMedCrossRef
11.
Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann Rev Cell Develop Biol 13:261–291CrossRef
12.
Mailand N, Diffley J (2005) CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122:915–926PubMedCrossRef
13.
Harper JW, Elledge SJ (1998) The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 12:285–289PubMedCrossRef
14.
Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ (1998) Human and yeast Cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9:2545–2560PubMed
15.
Fesquet D, Morin N, Doree M, Devault A (1997) Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts? Oncogene 15:1303–1307PubMedCrossRef
16.
Akoulitchev S, Makela T, Weinberg R, Reinberg D (1995) Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature 377:557–560PubMedCrossRef
17.
Busso D, Keriel A, Sandrock B et al (2000) Distinct regions of MAT1 regulate cdk7 kinase and TFIIH transcription activities. J Biol Chem 275:22815–22823PubMedCrossRef
18.
Hirose Y, Ohkuma Y (2007) Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem Tokyo 141:601–608PubMed
19.
Lee TI, Young RA (2000) Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34:77–137PubMedCrossRef
20.
Misra RN, H-y Xiao, Kim KS et al (2004) N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728PubMedCrossRef
21.
Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383–1395PubMedCrossRef
22.
Yasui H, Hideshima T, Richardson P, Anderson K (2006) Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 7:381–393PubMedCrossRef
23.
Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97:483–489PubMedCrossRef
24.
Chao S-H, Fujinaga K, Marion JE et al (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345–28348PubMedCrossRef
25.
Bach S, Knockaert M, Reinhardt J et al (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280:31208–31219PubMedCrossRef
26.
Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells. Cancer Res 56:2973–2978PubMed
27.
Losiewicz M, Carlson B, Kaur G, Sausville E, Worland P (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86–8275. Biochem Biophys Res Commun 201:589–595PubMedCrossRef
28.
McClue S, Blake D, Clarke R et al (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463–468PubMedCrossRef
29.
Squires MS, Feltell RE, Lock V et al (2007) AT7519, a potent CDK inhibitor, is active in leukemia models and primary CLL patient samples. ASH Annual Meeting Abstracts 110:3127
30.
Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513–2519PubMedCrossRef
31.
Merino R, Ding L, Veis D, Korsmeyer S, Nunez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13:683–691PubMed
32.
Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404PubMedCrossRef
33.
Bible KC, Lensing JL, Nelson SA et al (2005) Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 11:5935–5941PubMedCrossRef
34.
Chen R, Wierda WG, Benaissa S et al (2007) Mechanism of Action of SNS–032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. ASH Annual Meeting Abstracts 110:3112
35.
Heath E, Bible K, Martell R, Adelman D, Lorusso P (2008) A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59–65PubMedCrossRef
36.
Hawtin RE, Cohen R, Haas N et al (2007) In: 12th congress of the European Hematology Association Vienna, Austria, June 7–10, 2007. Haematologica, p 276
37.
Goldberg Z, Wierda W, Chen R et al (2008) In: 13th congress of the European Hematology Association Copenhagen, Denmark, June 12–15, 2008. Haematologica, p 327
38.
Bergsagel P (2007) Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma 7(Suppl 4):S170–S174PubMedCrossRef
39.
Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028PubMedCrossRef
40.
Ali M, Choy H, Habib A, Saha D (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9:370–381PubMedCrossRef
41.
Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303PubMedCrossRef
42.
Trudel S, Sebag M, Li ZH et al (2008) SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma. AACR Meeting Abstracts 2008, p 4972
43.
Metadata
Title
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Authors
Andrew Conroy
David E. Stockett
Duncan Walker
Michelle R. Arkin
Ute Hoch
Judith A. Fox
Rachael Elizabeth Hawtin
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0921-5

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

Original Article

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Letter to the Editor

MTT assays can underestimate cell numbers

Original Article

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

Original Article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells

Original Article

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits